Newsbenzinga
X4 Pharmaceuticals Says Phase 3 Mavorixafor Data In Chronic Neutropenia Expected Q1 2028; Announces Phase 2b Trial Starting Q1 2027
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…